advertisement
Abstract #23479 Published in IGR 11-2
Cost-efficacy analysis of fixed combinations of prostaglandin/prostamide for treating glaucoma
Martinez A; Slof JArchivos de la Sociedad Española de Oftalmologia 2008; 83: 595-600
OBJECTIVE: To assess the cost-efficacy of three fixed-combination glaucoma treatments currently available in Spain [bimatoprost with timolol (BT)-Ganfort(registered trademark), latanoprost with timolol (LT)- Xalacom(registered trademark), and travoprost with timolol (TT)- DuoTrav(registered trademark)]. METHODS: Because no studies are available that give a direct comparison of these drugs, a systematic review was carried out to assess their efficacy. Resource consumption and costs were estimated using a model of usual local practice. For each of the three drugs, average and incremental cost-efficacy ratios were determined in terms of euros per percentage point of reduction of intraocular pressure (IOP) over a three-month period. RESULTS: BT reduced IOP by 35.1%, LT by 35.0% and TT by 34.7%. Average cost-efficacy was estimated to be (euro) 5.34 per percentage point of IOP reduction with BT, (euro) 5.40 with LT, and (euro) 5.45 with TT. Incremental cost-efficacy (incremental cost per incremental percentage point of IOP reduction) was estimated to be (euro) 94.65 for LT vs. TT, and was negative for BT vs. TT and BT vs. LT, since in both cases BT was more efficacious and less expensive. CONCLUSIONS: Compared to travoprost/timolol and latanoprost/timolol, bimatoprost/timolol appears to be the most economic alternative, with equal or better efficacy and safety results. LA: Spanish
J. Slof. Departamento de Economia de la Empresa, Universidad Autonoma de Barcelona, 08193 Bellaterra (Barcelona), Spain. ericjohn.slof@uab.es
Classification:
11.13.4 Betablocker and prostaglandin (Part of: 11 Medical treatment > 11.13 Combination therapy)